Home/Browse by collection/Clinical/Translational Cancer Immunotherapy

Clinical/Translational Cancer Immunotherapy

Section Edited by Douglas G. McNeel, MD, PhD; Claudia Palena, PhD; and Jeffrey S. Weber, MD, PhD First-in-man clinical trials (prospective clinical data only); phase II/III clinical studies; immune monitoring investigations;.

Showing results 61 - 70 of 100

Sorted by most recent

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Dirk Schadendorf, Jason John Luke, Paolo A Ascierto, Georgina V Long, Piotr Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz-Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S CarlinoSee the full list of authors

13 March 2024